Announcement of Head Quarters Relocation
and Establishment of New Laboratory

Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a deep tech start-up developing a novel cell therapy, announced the relocation of its headquarters office to the Harumi Center Building (Chuo-ku, Tokyo) and the opening of a new in-house research facility.

The relocation has enabled us to open our own laboratory in line with the progress of our business, and by combining the head office functions with the laboratory, we have created an environment that will invigorate communication and further strengthen collaboration. Taking advantage of this, we will further accelerate research and development, aiming to contribute to patients around the world who are waiting for treatment.

■Office – Designed to meet a variety of needs –
Open space for casual collaboration, booths for concentrated work, and other office spaces where people can freely choose where they want to work.

■Laboratory – Newly established to increase flexibility and promote development –
By opening our own laboratory, we will be able to provide a full range of equipment and facilities that are optimal for our research and development, as well as experimental space that can accommodate research expansion.

[Overview of New Headquarters]
Address:
Harumi Center bldg. 5th floor, 2-5-24 Chuo, Tokyo 104-0053
Access:
9 minutes’ walk from Exit A2a of Kachidoki Station (Toei Oedo Line)
14 minutes’ walk from Exit 10 of Tsukishima Station (Tokyo Metro Yurakucho Line and Toei Oedo Line)

[About Cellusion]
Cellusion is a regenerative medicine start-up originating from the Department of Ophthalmology, Keio University School of Medicine, with “Regenerating Human Potential” as its mission and “More Freedom and More Smiles to the World” as its vision. Based on patented technology such as its proprietary technique of efficiently producing corneal endothelial substitute cell from iPS cells, Cellusion is promoting R&D aimed at meeting medical needs from the perspective of “patient centricity” by leveraging cutting-edge regenerative medicine technology, including the lead program CLS001 that aims to meet the global corneal transplant demands.

Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: Harumi Center bldg. 5th floor, 2-5-24 Harumi, Chuo, Tokyo 104-0053
Founded: January 2015
URL: https://cellusion.jp/en/

For further information: please ask us through the contact form on our website.